-$1.80 Earnings Per Share Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter

Share on StockTwits

Brokerages predict that Ascendis Pharma A/S (NASDAQ:ASND) will post ($1.80) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($1.56) and the lowest is ($2.05). Ascendis Pharma A/S reported earnings of ($0.59) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 205.1%. The business is expected to report its next earnings results on Monday, November 16th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($7.24) per share for the current financial year, with EPS estimates ranging from ($8.11) to ($6.33). For the next fiscal year, analysts anticipate that the business will report earnings of ($7.07) per share, with EPS estimates ranging from ($10.22) to ($1.60). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, August 27th. The biotechnology company reported ($1.97) EPS for the quarter, missing the consensus estimate of ($1.66) by ($0.31). Ascendis Pharma A/S had a negative net margin of 3,130.03% and a negative return on equity of 45.97%. The company had revenue of $1.58 million for the quarter, compared to analyst estimates of $2.47 million.

ASND has been the topic of a number of recent research reports. Morgan Stanley increased their target price on Ascendis Pharma A/S from $179.00 to $194.00 and gave the stock an “overweight” rating in a research note on Tuesday. Credit Suisse Group increased their target price on Ascendis Pharma A/S from $154.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, August 28th. Zacks Investment Research lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, September 2nd. BidaskClub lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Finally, JPMorgan Chase & Co. began coverage on Ascendis Pharma A/S in a report on Monday, September 14th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $171.42.

NASDAQ:ASND traded up $0.97 on Monday, hitting $158.47. The company’s stock had a trading volume of 153,423 shares, compared to its average volume of 207,224. The company has a current ratio of 9.04, a quick ratio of 9.04 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average of $149.49 and a two-hundred day moving average of $141.31. The firm has a market capitalization of $8.37 billion, a P/E ratio of -25.98 and a beta of 0.83. Ascendis Pharma A/S has a one year low of $92.00 and a one year high of $166.99.

Several hedge funds have recently modified their holdings of the business. Ensign Peak Advisors Inc boosted its holdings in shares of Ascendis Pharma A/S by 6.3% during the 2nd quarter. Ensign Peak Advisors Inc now owns 45,669 shares of the biotechnology company’s stock valued at $6,755,000 after acquiring an additional 2,711 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $385,000. Nuveen Asset Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 6.6% during the 1st quarter. Nuveen Asset Management LLC now owns 17,628 shares of the biotechnology company’s stock valued at $1,985,000 after acquiring an additional 1,092 shares in the last quarter. Comerica Bank boosted its holdings in shares of Ascendis Pharma A/S by 8.0% during the 2nd quarter. Comerica Bank now owns 15,206 shares of the biotechnology company’s stock valued at $2,167,000 after acquiring an additional 1,123 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in shares of Ascendis Pharma A/S by 39.6% during the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,540 shares of the biotechnology company’s stock valued at $375,000 after acquiring an additional 720 shares in the last quarter. 91.39% of the stock is currently owned by hedge funds and other institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.